Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats

Investigative Radiology

Volumn 51, Issue 2, 2016, Pages 73-82

  Robert, Philippe ^a   Violas, Xavier ^a   Grand, Sylvie ^b   Lehericy, Stéphane ^c,d,e   Idée, Jean Marc ^a   Ballet, Sébastien ^a   Corot, Claire ^a  

^a Guerbet Group Research   (France)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cumulative doses; Deep cerebellar nuclei; Dentate nucleus; Gadobenate dimeglumine; Gadodiamide; Gadolinium contrast agent; Gadopentetate dimeglumine; Gadoterate meglumine; Magnetic resonance

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; SODIUM CHLORIDE; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CEREBELLUM CORTEX; CEREBELLUM NUCLEUS; CONTROLLED STUDY; DEEP CEREBELLAR NUCLEI; DENTATE NUCLEUS; DRUG BRAIN LEVEL; DRUG RETENTION; FEMALE; IMAGE ANALYSIS; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; METABOLIC CLEARANCE RATE; METABOLISM; PROCEDURES; REFERENCE VALUE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; CEREBELLAR NUCLEI; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; MAGNETIC RESONANCE IMAGING; MEGLUMINE; METABOLIC CLEARANCE RATE; ORGANOMETALLIC COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 84953636482     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000241     Document Type: Article

References (44)

1. Adin ME, Kleinberg L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol. 2015;36:1859-1865.
2. Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685-690.
3. Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228-232.
4. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidusonunenhanced T1-weightedMRimages: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
5. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803-809.
6. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782.
7. Quattrocchi CC, Mallio CA, Errante Y, et al. High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology. 2015; 276:616-617.
8. Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
9. Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783-791.
10. Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015;276:836-844.
11. Roberts DR, Holden KR. Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pedi-atric brain exposed to multiple doses of gadolinium contrast. Brain Dev. 2015. [Epub ahead of print].
12. Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobu-trol. Eur Radiol. 2015. [Epub ahead of print].
13. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dime-glumine administration. Invest Radiol. 2015;50:743-748.
14. Kanda T, Oba H, Toyoda K, et al. Recent advances in understanding gadolinium retention in the brain. AJNR Am J Neuroradiol. 2015. [Epub ahead of print].
15. Radbruch A, Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805-810.
16. Runge VM. Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50: 481-482.
17. Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology. 2015;275:630-634.
18. Runge VM. Macrocyclic versus linear gadolinium chelates. Invest Radiol. 2015; 50:811.
19. Montagne A, Toga AW, Zlokovic BV. Blood-brain barrier permeability and gadolinium: benefits and potential pitfalls in research. JAMA Neurol. 2015:1-2.
20. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
21. Fretellier N, Idee JM, Dencausse A, et al. Comparative invivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011; 46:292-300.
22. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents inhuman serum at 37degrees C. Invest Radiol. 2008;43:817-828.
23. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272-278.
24. Agris J, Pietsch H, Balzer T. What evidence is there that gadobutrol causes increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W MRI in patients with RRMS? Eur Radiol. 2015. [Epub ahead of print].
25. Stojanov DA. Reply to letter to the editor re: increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2015. [Epub ahead of print].
26. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebel-lar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50:473-480.
27. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with en-dogenously available ions. Magn Reson Imaging. 1991;9:409-415.
28. Port M, Idee JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
29. CfDEaR UFaDA. Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: FDA, ed; 2005. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed July 6, 2005.
30. Oksendal AN, Hals PA. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging. 1993;3:157-165.
31. Hirano S, Suzuki KT. Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect. 1996;104(suppl 1):85-95.
32. Birka M, Wentker KS, Lusmoller E, et al. Diagnosis of nephrogenic systemic fi-brosis by means of elemental bioimaging and speciation analysis. Anal Chem. 2015;87:3321-3328.
33. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
34. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582; author reply 4-5.
35. Diedrichsen J, Balsters JH, Flavell J, et al. A probabilistic MR atlas of the human cerebellum. Neuroimage. 2009;46:39-46.
36. Maschke M, Weber J, Dimitrova A, et al. Age-related changes of the dentate nuclei in normal adults as revealed by 3D fast low angle shot (FLASH) echo sequence magnetic resonance imaging. J Neurol. 2004;251:740-746.
37. Popescu BF, Robinson CA, Rajput A, et al. Iron, copper, and zinc distribution of the cerebellum. Cerebellum. 2009;8:74-79.
38. Rajan MT, Jagannatha Rao KS, Mamatha BM, et al. Quantification of trace elements in normal human brain by inductively coupled plasma atomic emission spectrometry. J Neurol Sci. 1997;146:153-166.
39. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18:2636-2643.
40. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998;33:798-809.
41. Bousquet JC, Saini S, Stark DD, et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology. 1988;166:693-698.
42. Lorusso V, Arbughi T, Tirone P, et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr. 1999;23(suppl 1):S181-S194.
43. Dietrichs E. Clinical manifestation of focal cerebellar disease as related to the organization of neural pathways. Acta Neurol Scand Suppl. 2008;188:6-11.
44. Woodruff BK, Wijdicks EF, Marshall WF. Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med. 2002;346:68-69.